Abstract
Children with juvenile rheumatoid arthritis (JRA) have been reported to require higher doses (per kg body weight) of methotrexate (MTX) than adults with rheumatoid arthritis to control their disease. The purpose of the present study was to characterise the plasma pharmacokinetics of MTX and its major metabolite, 7-hydroxymethotrexate (7-OHMTX) in children, and to compare the results with those previously obtained in adults. Thirteen patients (age 5–16 y) with JRA (median disease duration 5.5 y) were studied after once weekly oral administration of MTX (median 0.21 mg·kg−1).
The analytical method was sufficiently sensitive to permit determination of plasma and urinary concentrations of MTX and 7-OHMTX during the entire dose interval in most of the patients.
The dose normalized area under the plasma concentration versus time-curve (AUC) of MTX increased with the age of the children and was lower than previously found in adults. The dose normalized AUC of 7-OHMTX was not dependent on age. No correlation was found between the AUCs of MTX and 7-OHMTX.
The results suggest that the age-dependence of the pharmacokinetics of MTX might explain the observation that at least some children require higher doses of MTX than adults to obtain a sufficient therapeutic effect.
Similar content being viewed by others
References
McBurney MW, Whitmore GF (1975) Mechanism of growth inhibition by methotrexate. Cancer Res 35: 586–590
Hryniuk W, Bertino JR (1971) Growth rate and cell kill. Ann NY, Acad Sci 186: 330–342
Skinner M, Schwartz R (1972) Immunosuppressive therapy. N Engl J Med 287: 221–227
Furst DE (1985) Clinical pharmacology of very low dose methotrexate for use in rheumatoid arthritis. J Rheumatol 12: 11–14
Furst DE, Kremer JM (1988) Methotrexate in rheumatoid arthritis. Arthritis Rheum 31: 305–314
Seideman P (1993) Methotrexate. The relationship between dose and clinical effect. Br J Rheumatol 32: 751–753
Shen DD, Azarnoff DL (1978) Clinical pharmacokinetics of methotrexate. Clin Pharmacokinet 3: 1–13
Edelman J, Biggs DF, Jamali F, Russell AS (1984) Low-dose methotrexate kinetics in arthritis. Clin Pharmacol Ther 35: 382–386
Sinnett MJ, Groff GD, Raddatz DA, Franck WA, Bertino JJ (1989) Methotrexate pharmacokinetics in patients with rheumatoid arthritis. J Rheumatol 16: 745–748
Herman RA, Pedersen-Veng P, Hoffman J, Koehnke R, Furst DE (1989) Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients. J Pharm Sci 78: 165–171
Seideman P, Beck O, Eksborg S, Wennberg M (1993) The pharmacokinetics of methotrexate and its 7-hydroxy metabolite in patients with rheumatoid arthritis. Br J Clin Pharmacol 35: 409–412
Stewart CF, Fleming RA, Arkin CR, Evans WE (1990) Coadministration of naproxen and low-dose methotrexate in patients with rheumatoid arthritis. Clin Pharmacol Ther 47: 540–546
Stewart CF, Fleming RA, Germain BF, Seleznick MJ, Evans WE (1991) Aspirin alters methotrexate disposition in rheumatoid arthritis patients. Arthritis Rheum 34: 1514–1520
Evans WE, Crom WR, Sinkule JA, Yee GC, Stewart CF, Hutson PR (1983) Pharmacokinetics of anticancer drugs in children. Drug Metab Rev 14: 847–886
Evans WE, Schell MJ, Pui CH (1990) MTX clearance is more important for intermediate-risk ALL. J Clin Oncol 8: 1115–1116
Borsi JD, Sagen E, Romslo I, Moe PJ (1990) Pharmacokinetics of folinic acid in children with acute lymphoblastic leukemia. Haematol Bluttransfus 33: 118–121
Wallace CA, Sherry DD (1992) Preliminary report of higher dose methotrexate treatment in juvenile rheumatoid arthritis. J Rheumatol 19: 1604–1607
Rose C, Singsen B, Eichenfield A, Goldsmith D, Athreya B (1990) Safety and efficacy of methotrexate therapy for Juvenile rheumatoid arthritis. J Pediatr 177: 653–659
Giannini EH, Brewer EJ, Kuzmina N, Shaikov A, Maximov A, Vorontsov I, Fink CW, Newman AJ, Cassidy JT, Zemel LS (1992) Methotrexate in resistant juvenile rheumatoid arthritis. Results of the USA-USSR double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group. N Engl J Med 326: 1043–1049
Brewer E, Bass J, Baum J, Cassidy J, Fink C, Jacobs J, Hanson V, Levinson J, Schaller J, Stillman J (1977) Current proposed revision of JRA criteria. Arthritis Rheum 20 [Suppl]: 195–199
Beck O, Seideman P, Wennberg M, Peterson C (1991) Trace analysis of methotrexate and 7-hydroxymethotrexate in human plasma and urine by a novel high-performance liquid chromatographic method. Ther Drug Monit 13: 528–532
Statistical Consultants I (1986) Pcnonlin and nonlin84: Software for statistical analysis of nonlinear models. The American Statistician 40: 52
Boxenbaum H, Riegelman S, Elashoff R (1974) Statistical estimation in pharmacokinetics. J Pharmacokinet Biopharm 2: 123–148
Daniel WW (1978) Applied nonparametric statistics. Houghton Mifflin Company Boston
Dallal G (1988) Pitman. A Fortran program for exact randomization tests. Comput Biomed Res 21: 9–15
Skoglund KA, Söderhäll S, Beck O, Peterson C, Wennberg M, Hayder S, Björk O (1994) Plasma and urine levels of methotrexate and 7-hydroxymethotrexate in children with ALL during maintenance therapy with weekly oral methotrexate. Med Pediatr Oncol 22: 187–193
Wallace CA, Bleyer WA, Sherry DD, Salmonson KL, Wedgwood RJ (1989) Toxicity and serum levels of methotrexate in children with juvenile rheumatoid arthritis. Arthritis Rheum 32: 677–681
Balis FM, Savitch JL, Bleyer WA (1983) Pharmacokinetics of oral methotrexate in children. Cancer Res 43: 2342–2345
Pinkerton CR, Welshman SG, Glasgow JF, Bridges JM (1980) Can food influence the absorption of methotrexate in children with acute lymphoblastic leukaemia? Lancet II: 944–946
Oguey D, Kölliker F, Gerber NJ, Reichen J (1992) Effect of food on the bioavailability of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum, 35: 611–614
Ravelli A, Di Fucci G, Molinaro M, Ramenghi B, Zonta L, Regazzi M, Martini A (1993) Plasma levels after oral methotrexate in children with juvenile rheumatoid arthritis. J Rheumatol 20: 1573–1577
Evans WE, Crom WR, Stewart CF, Bowman WP, Chen CH, Abromowitch M, Simone JV (1984) Methotrexate systemic clearance influences probability of relapse in children with standard-risk acute lymphocytic leukaemia. Lancet I: 359–362
Borsi JD, Moe PJ (1987) Systemic clearance of methotrexate in the prognosis of acute lymphoblastic leukemia in children. Cancer 60: 3020–3024
Donelli MG, Zucchetti M, Masera G, DÍncalci M, Robatto A, Rossi MR (1993) Pharmacokinetis of HD-MTX (5 g i.v. sq.m) in infants, children and adolescents with non B-acute lymphoblastic leukemia. Proc ASCO 12: 150
Najjar TA, Alfawaz IM (1993) Pharmacokinetics of methotrexate in children with acut lymphocytic leukemia. Chemotherapy 39: 242–247
Koren G, Gorodischer R (1992) Digoxin. In: Aranda J (ed) Pediatric pharmacology. Therapeutic principales in practice. Saunders, Philadelphia, pp 355–364
Jalling B, Boréus L, Rane A, Sjöqvist F (1970) Plasma concentrations of diphenylhydantoin in young infants. Pharmacol Clin 2: 2000–2002
Seideman P, Albertioni F, Beck O, Eksborg S, Peterson C (1994) Chloroquine reduces bioavailability of methotrexate in patients with rheumatoid arthritis — a possible mechanism for reduced hepatotoxicity. Arthritis Rheum 37: 830–833
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Albertioni, F., Beck, O., Peterson, C. et al. Methotrexate in juvenile rheumatoid arthritis. Eur J Clin Pharmacol 47, 507–511 (1995). https://doi.org/10.1007/BF00193703
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00193703